Moderna is now expecting 2025 research and development costs of about $4.1 billion and selling, general and administrative costs of about $1.1 billion. Cost of sales is expected to come to about $1.2 ...

Vizient Quality and Accountability Ranking. Ranked #1 out of 115 participating comprehensive academic medical centers." ...

Corbus Pharmaceuticals presented Phase 1 data on CRB-701 at ASCO GU, showing safety, tolerability, and responses across multiple tumor types.

Two months after Allogene abandoned plans for its CAR-T in leukemia, analysts have suggested that fresh phase 1 data in ...

The American Cancer Society's chief scientific officer outlines the group's research agenda, including a new project in ...

Clinical trials have been pivotal to the improvements in public health and clinical care, leading to many millions of ...

Nuvation has a best-in-class lung cancer drug that could be approved in the US in June. Read why I'm bullish on the stock ...

Valuation discrepancies in the biotech sector highlight Shuttle Pharma’s incredible potential. With several peer companies in ...

Two new measures tied to outcomes drawn from data in the CLEAR phase 3 trial will be presented during the ASCO Genitourinary ...

The research offers hope to tens of thousands of patients with kidney failure who are on a long waiting list for an organ transplant.

Tectonic Therapeutic said the findings support the design and population for Phase 2 APEX trial, which will test TX45 in ...